This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Cresemba in Invasive Aspergillosis: Adverse Events

In the SECURE trial, CRESEMBA® demonstrated significantly fewer AEs vs. voriconazole1. With fewer discontinuations than voriconazole, CRESEMBA could give your patients a better chance of tolerating treatment1. CRESEMBA specifically showed significantly reduced hepatic, eye and skin toxicity vs. voriconazole.

Toxicity (safety population)​​​​​​​1

CRESEMBA
(N=257)

Voriconazole
(n=259)

Study drug-related
TEAEs (p<0.001)

42%

60%

TEAEs leading to discontinuation (p=NS)

14%

14%

Study drug-related AEs leading to discontinuation (p=NS)

8%

8%

Explore More

Mucormycosis

An overview of the VITAL trial for CRESEMBA (isavuconazole)​​​​​​​

Learn more


References:
  1. ​​​​​​​​​​​​​​Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voricanazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE); a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
PP-CRB-GBR-1205. August 2021

Invasive Aspergillosis (Quick Links)

Safety Profile

 CRESEMBA safety information

Dosing

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Access dosing information

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No